Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;43:263-269
Published online before print January 5, 2004, doi: 10.1161/01.HYP.0000113627.08110.6f
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
43/2/263    most recent
01.HYP.0000113627.08110.6fv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jinno, T.
Right arrow Articles by Horiuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jinno, T.
Right arrow Articles by Horiuchi, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors

(Hypertension. 2004;43:263.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Calcium Channel Blocker Azelnidipine Enhances Vascular Protective Effects of AT1 Receptor Blocker Olmesartan

Toyohisa Jinno; Masaru Iwai; Zhen Li; Jian-Mei Li; Hong-Wei Liu; Tai-Xing Cui; Hiromi Rakugi; Toshio Ogihara; Masatsugu Horiuchi

From Department of Medical Biochemistry (T.J., M.I., Z.L., J.-M.L., H.-W.L., T.-X.C., M.H.), Ehime University School of Medicine, Ehime, Japan, and Department of Geriatric Medicine (H.R., T.O.), Graduate School of Medicine, Suita, Osaka Japan.

Correspondence to Dr Masatsugu Horiuchi, Department of Medical Biochemistry, Ehime University School of Medicine, Shigenobu, Onsen-gun, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

The present studies were undertaken to investigate the potential effect of a calcium channel blocker (CCB) to enhance the inhibitory effect of an angiotensin (Ang) II type 1 (AT1) receptor blocker (ARB) on vascular injury and the cellular mechanism of the effect of CCB on vascular remodeling. In polyethylene cuff-induced vascular injury of the mouse femoral artery, proliferation of vascular smooth muscle cells (VSMCs) and neointimal formation associated with activation of extracellular signal-regulated kinase (ERK), and tyrosine-phosphorylation of signal transducer and activator of transcription (STAT)1 and STAT3, inflammatory response assessed by monocyte chemoattractant protein-1 and tumor necrosis factor-{alpha} expression, as well as oxidative stress such as expression of NADH/NADPH oxidase p22phox subunit and superoxide production, were less in AT1a receptor null mice. Administration of nonhypotensive doses of a CCB, azelnidipine (0.5 or 1 mg/kg per day) attenuated these parameters in wild-type and AT1a receptor null mice. Coadministration of lower doses of an ARB, olmesartan (0.5 mg/kg per day), and azelnidipine (0.1 mg/kg per day), which did not affect vascular remodeling, significantly inhibited these parameters in wild-type mice. Moreover, the effective dose of azelnidipine (1 mg/kg per day) exaggerated the inhibitory action of olmesartan at effective doses of 1 or 3 mg/kg per day on VSMC proliferation in the injured arteries. These results suggest that azelnidipine could inhibit vascular injury at least partly independent of the inhibition of AT1 receptor activation and that azelnidipine could exaggerate the vascular protective effects of olmesartan, suggesting clinical possibility that the combination of CCB and ARB could be more effective in the treatment of vascular diseases.


Key Words: angiotensin • calcium channel • oxidative stress • vascular remodeling • inflammation




This article has been cited by other articles:


Home page
HypertensionHome page
A.-i. Shigenaga, K. Tamura, H. Wakui, S.-i. Masuda, K. Azuma, Y. Tsurumi-Ikeya, M. Ozawa, M. Mogi, M. Matsuda, K. Uchino, et al.
Effect of Olmesartan on Tissue Expression Balance Between Angiotensin II Receptor and Its Inhibitory Binding Molecule
Hypertension, October 1, 2008; 52(4): 672 - 678.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Hagita, M. Osaka, K. Shimokado, and M. Yoshida
Oxidative Stress in Mononuclear Cells Plays a Dominant Role in Their Adhesion to Mouse Femoral Artery After Injury
Hypertension, March 1, 2008; 51(3): 797 - 802.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Iwai, H.-S. Li, R. Chen, T. Shiuchi, L. Wu, L.-J. Min, J.-M. Li, M. Tsuda, J. Suzuki, Y. Tomono, et al.
Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1081 - 1087.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Oshita, M. Iwai, R. Chen, A. Ide, M. Okumura, S. Fukunaga, T. Yoshii, M. Mogi, J. Higaki, and M. Horiuchi
Attenuation of Inflammatory Vascular Remodeling by Angiotensin II Type 1 Receptor-Associated Protein
Hypertension, October 1, 2006; 48(4): 671 - 676.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Okumura, M. Iwai, A. Ide, M. Mogi, M. Ito, and M. Horiuchi
Sex Difference in Vascular Injury and the Vasoprotective Effect of Valsartan Are Related to Differential AT2 Receptor Expression
Hypertension, September 1, 2005; 46(3): 577 - 583.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J.-M. Li, M. Iwai, T.-X. Cui, L.-J. Min, M. Tsuda, J. Iwanami, J. Suzuki, M. Mogi, and M. Horiuchi
Effect of Azelnidipine on Angiotensin II-Mediated Growth-Promoting Signaling in Vascular Smooth Muscle Cells
Mol. Pharmacol., May 1, 2005; 67(5): 1666 - 1673.
[Abstract] [Full Text] [PDF]